Want to see IN:NATCAPSUQ full AI Analyst Report?
Top Page
Natural Capsules Limited
(NATCAPSUQ)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹217.00
▲(49.50% Upside)
Action:Reiterated
Date:08/28/26
The score is held back primarily by weak financial performance—margin collapse, a shift to net loss, and negative free cash flow that raises funding risk. This is partially offset by strong technical strength with the stock trading above all key moving averages and positive momentum, while valuation remains challenged due to losses (negative P/E) and no stated dividend yield.
Positive Factors
Revenue Expansion
FY2026 revenue growth indicates the company expanded its top line despite weak earnings. Sustained sales growth can broaden the revenue base and support future operating leverage if pricing, mix, and costs are brought under control.
Negative Factors
Severe Profitability Deterioration
The shift from near break-even results to a sizable loss shows that revenue growth is not currently converting into sustainable profits. Negative operating and EBITDA margins point to cost, pricing, or product-mix pressure that could persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Expansion
FY2026 revenue growth indicates the company expanded its top line despite weak earnings. Sustained sales growth can broaden the revenue base and support future operating leverage if pricing, mix, and costs are brought under control.
Read all positive factors
Natural Capsules Limited (NATCAPSUQ) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.96B
Dividend Yield0.4%
Average Volume (3M)7.95K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue Growth8.84%
EPS Growth-285.42%
CountryIN
Employees620
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-6.25
Shares Outstanding10,411,154
10 Day Avg. Volume5,000
30 Day Avg. Volume7,946
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)0.55
P/FCF Ratio-9.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Natural Capsules Limited Business Overview & Revenue Model
Company Description
Natural Capsules Ltd. specializes in the production and global distribution of hard gelatin and cellulose capsule shells, catering to markets in India and abroad. The company offers a comprehensive array of capsule types, including those guarantee...
Natural Capsules Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 857.19M | 1.87B | 1.64B |
| Gross Profit | 350.75M | 467.09M | 757.25M |
| EBITDA | 39.63M | 1.72M | 182.22M |
| Net Income | -64.68M | -170.74M | 6.17M |
Balance Sheet | |||
| Total Assets | 4.20B | 4.24B | 4.19B |
| Cash, Cash Equivalents and Short-Term Investments | 53.75M | 48.23M | 51.98M |
| Total Debt | 1.12B | 1.15B | 1.05B |
| Total Liabilities | 1.75B | 1.89B | 1.62B |
| Stockholders Equity | 2.27B | 2.22B | 2.33B |
Cash Flow | |||
| Free Cash Flow | -115.70M | -106.77M | -178.78M |
| Operating Cash Flow | 201.52M | 8.53M | 267.52M |
| Investing Cash Flow | -313.49M | -115.30M | -444.85M |
| Financing Cash Flow | 25.08M | 102.16M | 161.67M |
Natural Capsules Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.73B | 12.03 | ― | 0.70% | 4.29% | 2.40% | |
60 Neutral | ₹1.95B | 14.78 | ― | ― | -7.71% | 927.75% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹1.30B | 36.31 | ― | ― | 0.46% | -83.31% | |
52 Neutral | ₹1.96B | -8.47 | ― | 0.40% | 8.84% | -285.42% | |
49 Neutral | ₹1.71B | 23.72 | ― | 1.12% | 13.51% | -14.80% | |
48 Neutral | ₹2.23B | -1.02 | ― | 20.72% | -99.53% | -41.93% |
* General Sector Average
IN:NATCAPSUQ
Natural Capsules Limited
188.50
-2.30
-1.21%
IN:ALPA
Alpa Laboratories Limited
61.85
-32.64
-34.54%
IN:BALPHARMA
Bal Pharma Limited
107.47
20.92
24.17%
IN:BROOKS
Brooks Laboratories Limited
66.25
-91.80
-58.08%
IN:NECLIFE
Nectar Lifesciences Ltd.
11.50
-5.04
-30.47%
IN:PAR
Par Drugs and Chemicals Limited
140.92
35.15
33.23%
Natural Capsules Limited Corporate Events
Natural Capsules posts June 2 conference call audio for investors
Jun 2, 2026
Natural Capsules Limited has notified stock exchanges that the audio recording of its conference call held on June 2, 2026 has been made available on the company’s website. The move reflects the company’s adherence to SEBI’s disc...
Natural Capsules Resets Investor Call Link Ahead of FY26 Earnings Discussion
Jun 1, 2026
Natural Capsules Limited has notified stock exchanges that, following a technical error in its earlier communication, it is republishing the corrected access details for its upcoming investor and analyst conference call. The call is scheduled for ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.